Page 2 - Havah Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Havah therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Havah Therapeutics Today - Breaking & Trending Today

Clarus Therapeutics (OTCMKTS:CRXTQ) and Innate Pharma (OTCMKTS:IPHYF) Head-To-Head Survey

Clarus Therapeutics (OTCMKTS:CRXTQ – Get Rating) and Innate Pharma (OTCMKTS:IPHYF – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings. Volatility and Risk Clarus Therapeutics has a beta of […] ....

United States , Eric Vivier , Marc Bonneville , Jean Jacques Fourni , Alessandro Moretta , Eloi Dominique Brailly , Clarus Therapeutics Holdings Inc , Clarus Therapeutics , Get Rating , Innate Pharma , Therapeutics Holdings , Havah Therapeutics , Royal Institution , Mcgill University , Clarus Therapeutics Daily , Otcmkts Crxtq , Stock Comparison , Stock Analysis ,

Comparing Clarus Therapeutics (NASDAQ:CRXT) & SOPHiA GENETICS (NASDAQ:SOPH)

Clarus Therapeutics (NASDAQ:CRXT – Get Rating) and SOPHiA GENETICS (NASDAQ:SOPH – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability. Analyst Ratings This is a summary of current ratings […] ....

United States , Saint Sulpice , Switzerland General , Company Profile Get Rating , Clarus Therapeutics Company Profile Get Rating , Clarus Therapeutics Holdings Inc , Clarus Therapeutics , Get Rating , Given Clarus Therapeutic , Therapeutics Company Profile , Therapeutics Holdings , Havah Therapeutics , Royal Institution , Mcgill University , Nasdaq Crxt , Stock Comparison , Stock Analysis ,

Short Interest in Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT) Increases By 433.3%

Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT – Get Rating) saw a significant growth in short interest during the month of May. As of May 31st, there was short interest totalling 2,780,000 shares, a growth of 433.3% from the May 15th total of 521,300 shares. Currently, 10.6% of the company’s shares are sold short. Based on an […] ....

United States , Powell Investment Advisors , Renaissance Technologies , Needham Company , Maxim Group , Verition Fund Management , Clarus Therapeutics Holdings Inc , Clarus Therapeutics Holdings , Get Rating , Clarus Therapeutics , Truist Financial , Investment Advisors , Fund Management , Therapeutics Holdings , Havah Therapeutics , Royal Institution , Mcgill University , Nasdaq Crxt ,

Clarus Therapeutics (NASDAQ:CRXT) Price Target Lowered to $1.50 at Maxim Group

Clarus Therapeutics (NASDAQ:CRXT – Get Rating) had its target price reduced by analysts at Maxim Group to $1.50 in a note issued to investors on Thursday, Stock Target Advisor reports. Maxim Group’s price target suggests a potential upside of 284.52% from the stock’s current price. Several other analysts have also recently issued reports on the […] ....

United States , Powell Investment Advisors , Clarus Therapeutics Company Profile Get Rating , Zacks Investment Research , Renaissance Technologies , Needham Company , Maxim Group , Verition Fund Management , Clarus Therapeutics Holdings Inc , Clarus Therapeutics , Get Rating , Stock Target Advisor , Investment Research , Truist Financial , Fund Management , Investment Advisors , Therapeutics Company Profile , Therapeutics Holdings , Havah Therapeutics , Royal Institution , Mcgill University , Target Advisor , Nasdaq Crxt , Lower Price Target ,

Clarus Therapeutics (NASDAQ:CRXT) PT Lowered to $3.00

Clarus Therapeutics (NASDAQ:CRXT – Get Rating) had its target price cut by equities researchers at Needham & Company LLC to $3.00 in a research note issued on Tuesday, Stock Target Advisor reports. The brokerage presently has a “buy” rating on the stock. A number of other equities analysts also recently issued reports on the stock. […] ....

United States , Schonfeld Strategic Advisors , Zacks Investment Research , Renaissance Technologies , Needham Company , Verition Fund Management , Citadel Advisors , Clarus Therapeutics Holdings Inc , Clarus Therapeutics , Get Rating , Stock Target Advisor , Strategic Advisors , Fund Management , Therapeutics Holdings , Havah Therapeutics , Royal Institution , Mcgill University , Target Advisor , Nasdaq Crxt , Lower Price Target , Needham Company Llc ,